Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Commentary|Articles|August 9, 2023
5 Questions on CDC Updates to COVID-19 and Flu Vaccine Guidance
Author(s)Kenneth Bender, PharmD, MA
Updates to CDC recommendations on influenza and COVID-19 vaccines and vaccine formulations will impact your choices during flu season this year.
Advertisement
New COVID-19 and influenza immunization recommendations from the Centers for Disease Control and Prevention (CDC) will affect vaccination decisions made during the 2023-2024 respiratory virus season. The updates reflect changes in the spread of infections as well as in the development of vaccines. The following 5 questions test what you know about recommended vaccines and vaccine formulations for these 2 soon-to-be-prevalent viruses.
Question 1. COVID-19 vaccination is recommended for everyone 6 months and older who is not immunocompromised.
Question 2. Which of the following COVID-19 vaccines is/are not currently recommended?
Question 3. With the development of bivalent COVID-19 vaccines, monovalent vaccines will not be used in 2023.
Question 4. Select recommended option(s) for persons aged ≥18 years who were previously vaccinated with the Janssen adenovirus vector COVID-19 vaccine.
Question 5. Select influenza vaccine(s) preferred by the CDC for those aged ≥65 years.
Sources include the 2023 CDC Immunization Schedules for
Advertisement
Related to this article
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
Advertisement
Advertisement
Trending on Patient Care Online
1
4 FDA Decisions for Primary Care to Know from October 2026
2
Abbott's Amulet 360 Linked to Low Stroke Risk at 1 Year in Late-Breaking Research
3
When Night Sweats Signal Something Other Than Menopause
4
New Schizophrenia Treatment Addresses Long-Standing LAI Barriers
5